Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease - PubMed (original) (raw)
Review
. 2017 Nov 27;56(1):5-18.
doi: 10.1515/cclm-2017-0120.
Affiliations
- PMID: 28672731
- DOI: 10.1515/cclm-2017-0120
Free article
Review
Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease
Zenthuja Sivalingam et al. Clin Chem Lab Med. 2017.
Free article
Abstract
Neutrophil gelatinase-associated lipocalin (NGAL) is a promising diagnostic biomarker of early acute kidney injury. Increasing evidence suggests that NGAL may also be involved in inflammatory processes in cardiovascular disease. NGAL modulates the enzymatic activity of matrix metalloproteinase-9 (MMP-9), which is an important mediator of plaque instability in atherosclerosis. The complex formation between NGAL and MMP-9 therefore suggests that NGAL might play a role in progression of atherothrombotic disease. This review summarises current data on NGAL in atherosclerosis, acute myocardial infarction, and heart failure.
Keywords: atherosclerosis; biomarkers; cardiovascular disease; inflammation; neutrophil gelatinase-associated lipocalin (NGAL).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous